Hansoh Pharma’s Ameile Gains New Drug Acceptance

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Hansoh Pharmaceutical’s new drug Ameile, a pioneering third-generation EGFR-TKI medication developed in China, has received acceptance from the National Medical Products Administration for its use in the adjunct treatment of non-small cell lung cancer with specific EGFR mutations. This marks Ameile’s third indication, following approvals for first-line and T790M mutation-positive treatments, underscoring its growing presence in the Chinese pharmaceutical market.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.